151 related articles for article (PubMed ID: 38138220)
21. Serous tubal intraepithelial carcinoma localizes to the tubal-peritoneal junction: a pivotal clue to the site of origin of extrauterine high-grade serous carcinoma (ovarian cancer).
Seidman JD
Int J Gynecol Pathol; 2015 Mar; 34(2):112-20. PubMed ID: 25675178
[TBL] [Abstract][Full Text] [Related]
22. Fallopian tube abnormalities in uterine serous carcinoma.
Steenbeek MP; Bulten J; Snijders MPLM; Lombaers M; Hendriks J; van den Brand M; Kraayenbrink AA; Massuger LFAG; Sweegers S; de Hullu JA; Pijnenborg JMA; Küsters-Vandevelde HVN; Reijnen C
Gynecol Oncol; 2020 Aug; 158(2):339-346. PubMed ID: 32409160
[TBL] [Abstract][Full Text] [Related]
23. Detection of serous precursor lesions in resected fallopian tubes from patients with benign diseases and a relatively low risk for ovarian cancer.
Nishida N; Murakami F; Higaki K
Pathol Int; 2016 Jun; 66(6):337-42. PubMed ID: 27250113
[TBL] [Abstract][Full Text] [Related]
24. [Pathologic features of fallopian tubal fimbriae in patients with endometrial serous carcinoma].
Mu T; Li H; Wang J; Yao Y; Shen D
Zhonghua Fu Chan Ke Za Zhi; 2015 Oct; 50(10):757-61. PubMed ID: 26675575
[TBL] [Abstract][Full Text] [Related]
25. Stathmin 1 and p16(INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma.
Novak M; Lester J; Karst AM; Parkash V; Hirsch MS; Crum CP; Karlan BY; Drapkin R
Gynecol Oncol; 2015 Oct; 139(1):104-11. PubMed ID: 26206555
[TBL] [Abstract][Full Text] [Related]
26. Are all pelvic (nonuterine) serous carcinomas of tubal origin?
Przybycin CG; Kurman RJ; Ronnett BM; Shih IeM; Vang R
Am J Surg Pathol; 2010 Oct; 34(10):1407-16. PubMed ID: 20861711
[TBL] [Abstract][Full Text] [Related]
27. The association of serous tubal intraepithelial carcinoma with gynecologic pathologies and its role in pelvic serous cancer.
Koç N; Ayas S; Uygur L
Gynecol Oncol; 2014 Sep; 134(3):486-91. PubMed ID: 25038287
[TBL] [Abstract][Full Text] [Related]
28. Mucosal carcinoma of the fallopian tube coexists with ovarian cancer of serous subtype only: a study of Japanese cases.
Maeda D; Ota S; Takazawa Y; Ohashi K; Mori M; Imamura T; Nakagawa S; Yano T; Taketani Y; Fukayama M
Virchows Arch; 2010 Nov; 457(5):597-608. PubMed ID: 20872013
[TBL] [Abstract][Full Text] [Related]
29. Relationship between the precursors of high grade serous ovarian cancer and patient characteristics: decreased incidence of the p53 signature in pregnant women.
Ida T; Fujiwara H; Kiriu T; Taniguchi Y; Kohyama A
J Gynecol Oncol; 2019 Nov; 30(6):e96. PubMed ID: 31576690
[TBL] [Abstract][Full Text] [Related]
30. [Preliminary study on the relationship between tubal intraepithelial carcinoma of the fimbria and pelvic high-grade serous carcinoma].
Liang Y; Chen XD; Lü BJ; Zhou CY; Zhang XF; Shi HY
Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):724-8. PubMed ID: 22321343
[TBL] [Abstract][Full Text] [Related]
31. [The morphological and immunohistochemical characteristics of changes in the fallopian tube mucosa in ovarian epithelial tumors].
Asaturova AV; Ezhova LS; Faizullina NM; Sannikova MV; Khabas GN
Arkh Patol; 2016; 78(2):3-9. PubMed ID: 27070769
[TBL] [Abstract][Full Text] [Related]
32. Expression of Cell Competition Markers at the Interface between p53 Signature and Normal Epithelium in the Human Fallopian Tube.
Kito M; Maeda D; Kudo-Asabe Y; Sato N; Shih IeM; Wang TL; Tanaka M; Terada Y; Goto A
PLoS One; 2016; 11(6):e0156069. PubMed ID: 27258067
[TBL] [Abstract][Full Text] [Related]
33. Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study.
Visvanathan K; Shaw P; May BJ; Bahadirli-Talbott A; Kaushiva A; Risch H; Narod S; Wang TL; Parkash V; Vang R; Levine DA; Soslow R; Kurman R; Shih IM
Cancer Prev Res (Phila); 2018 Nov; 11(11):697-706. PubMed ID: 30232083
[TBL] [Abstract][Full Text] [Related]
34. IMP3 as a cytoplasmic biomarker for early serous tubal carcinogenesis.
Wang Y; Li L; Wang Y; Yuan Z; Zhang W; Hatch KD; Zheng W
J Exp Clin Cancer Res; 2014 Jul; 33(1):60. PubMed ID: 25038792
[TBL] [Abstract][Full Text] [Related]
35. Do deeper sections increase the frequency of detection of serous tubal intraepithelial carcinoma (STIC) in the "sectioning and extensively examining the FIMbriated end" (SEE-FIM) protocol?
Mahe E; Tang S; Deb P; Sur M; Lytwyn A; Daya D
Int J Gynecol Pathol; 2013 Jul; 32(4):353-7. PubMed ID: 23722507
[TBL] [Abstract][Full Text] [Related]
36. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.
Norris EJ; Zhang Q; Jones WD; DeStephanis D; Sutker AP; Livasy CA; Ganapathi RN; Tait DL; Ganapathi MK
J Pathol; 2019 Jul; 248(3):352-362. PubMed ID: 30883751
[TBL] [Abstract][Full Text] [Related]
37. Immunophenotypic Analysis in Early Müllerian Serous Carcinogenesis.
Nafisi H; Ghorab Z; Ismill N; Dubé V; Plotkin A; Han G; Cesari M; Lu FI; Saad R; Khalifa M; Nofech-Mozes S
Int J Gynecol Pathol; 2015 Sep; 34(5):424-36. PubMed ID: 26107560
[TBL] [Abstract][Full Text] [Related]
38. Serous tubal intraepithelial carcinoma, chronic fallopian tube injury, and serous carcinoma development.
Malmberg K; Klynning C; Flöter-Rådestad A; Carlson JW
Virchows Arch; 2016 Jun; 468(6):707-13. PubMed ID: 27003156
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC).
Saccardi C; Zovato S; Spagnol G; Bonaldo G; Marchetti M; Alessandrini L; Tognazzo S; Guerriero A; Vitagliano A; Laganà AS; Noventa M
Gynecol Oncol; 2021 Nov; 163(2):364-370. PubMed ID: 34465478
[TBL] [Abstract][Full Text] [Related]
40. Evidence of a Monoclonal Origin for Bilateral Serous Tubal Intraepithelial Neoplasia.
Meserve EE; Strickland KC; Miron A; Soong TR; Campbell F; Howitt BE; Crum CP
Int J Gynecol Pathol; 2019 Sep; 38(5):443-448. PubMed ID: 29901519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
